Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

Release date

March 31, 2020

Expiration date

March 31, 2021

Estimated time to complete activity

15 minutes

Media

Internet

Program Overview

Despite the success of statin therapy in significantly reducing patients’ LDL-cholesterol and the risk of cardiovascular events, there remains a considerable need for event reduction. Fortunately, we now have findings from the REDUCE-IT landmark trial on icosapent ethyl that could help us find a way to meet that need.

This activity will provide practical information on the evidence, clinical utility, and use of icosapent ethyl in patients at risk of ASCVD events.

Target Audience

This on-line CME activity is targeted for Pharmacists.

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe the impact of recent randomized cardiovascular outcomes trials to reduce ASCVD risk
• Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
• Apply evidence-based guidelines, recent trial evidence, and cost utility of ASCVD therapy in practice

Faculty

Host
Deepak L. Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs,
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, MA

Daniel E. Hilleman, PharmD, FCCP
Professor and Director, Continuing Education
Creighton University School of Pharmacy and Health Professions
Omaha, NE

Mary Katherine Cheeley, PharmD, CLS, FNLA
Grady Health System
Atlanta, GA

Faculty Disclosures

Host
Deepak L. Bhatt, MD

FINANCIAL DISCLOSURE
Contracted Research: Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company

Faculty
Mary Katherine Cheeley, MD

FINANCIAL DISCLOSURE
Planners and Managers
Consulting Fees: Glaxo Smith Kline
Other:  Investigator Initiated Study Grant- Sanofi/Regeneron Alliance

Daniel E. Hilleman, MD

FINANCIAL DISCLOSURE
Consulting Fees:  Heron Therapeutics
Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Amarin

The PIM planners and managers have nothing to disclose. The Medtelligence planners and managers have nothing to disclose.

Accreditation and Credit Designation Statements
Joint Accreditation Statement

Jointly provided by Postgraduate Institute for Medicine and Medtelligence.
  

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medtelligence.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CONTINUING PHARMACY EDUCATION

Postgraduate Institute for Medicine designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education. 

(Universal Activity Number -  JA4008162-9999-20-2048-H01-P)
Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Required Computer Hardware/Software

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5